DLA Piper advised Servier in its exclusive license agreement with IDEAYA Biosciences for Darovasertib

DLA Piper assisted Servier, an international pharmaceutical group with headquarters in France, in the negotiation of an exclusive license agreement with IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company.

Under the agreement, Servier obtains the regulatory and commercial rights for darovasertib (a promising treatment for a rare eye cancer) in all territories outside the United States. IDEAYA retains its rights for darovasertib in the United States. Darovasertib, a potent and selective protein kinase C (PKC) inhibitor, is being developed to broadly address primary and metastatic uveal melanoma (UM).

IDEAYA will receive an upfront payment of USD210 million, and be eligible for up to US$320 million in regulatory approval-based and commercial milestone payments, as well as double-digit royalties on net sales in all territories outside of the United States. Servier will be responsible for the regulatory and commercial activities for darovasertib in all territories outside the United States. IDEAYA and Servier will collaborate on the development of darovasertib and share the associated costs.

This matter was led by Paris-based partner Sonia de Kondserovsky and included Marion Abecassis (Counsel) and Alexandre Diez (Associate) on the licensing transaction and life sciences aspects.
In Paris, the deal included:

• Denise Lebeau-Marianna (Partner) and Yaël Hirsch (Counsel) for Data Protection;
• Raphaël Bera (Partner) and Florian de Vienne (Associate) for Tax;
• Edouard Sarrazin (Partner) and Julie Brousseau (Counsel) for Competition.

In the US, Lauren Murdza (Partner) and Andrew Dietrick (Associate) provided input on US law aspects and
In the UK, John McKinlay (Partner) on UK law aspects.